Prostate Cancer Aggressiveness Gene in Hereditary Prostate Cancer
Abstract
This is the final report of our CDMRP-funded research grant. Our study comprised of two research aims to examine the role of EZH2 and prostate cancer. In the first of these aims, we have explored and developed data indicating that a polymorphism in EZH2, Asp146His, may contribute to aggressive prostate cancer, and we are currently conducting validation studies to determine if our findings may be used to predict whether men with prostate cancer will have a more aggressive clinical course. This may lead to the recommendation of more aggressive therapies based on genotype. In the second aim, we demonstrated that for the first time that the chromatin-remodeling protein EZH2 interacts with the nuclear receptor REA. This observation begins to shed light on how EZH2 may function in hormonally-regulated tissues, and raises the intriguing possibility that targeted intervention of these factors involved in chromatin remodeling may represent a novel area for the future design of pharmacologic agents for the treatment of prostate cancer.
Document Details
- Document Type
- Technical Report
- Publication Date
- Mar 01, 2007
- Accession Number
- ADA472110
Entities
People
- Kathleen A. Cooney
Organizations
- University of Michigan